2026-09-25 11:44:32 UTC#368297duplicateconfirmedpress release
Johnson & Johnson (JNJ) stock news
Johnson & Johnson (JNJ) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-09-25 11:30:00 UTC#368271duplicateconfirmedpress release
Johnson & Johnson's TREMFYA meets primary endpoints in Phase 4 STAR study for axial psoriatic arthritis
2026-09-25 11:30:00 UTC#368242newconfirmedpress release
J&J's TREMFYA shows significant improvement in spinal pain and stiffness in axial psoriatic arthritis study
2026-09-25 11:16:00 UTC#368227duplicateconfirmedpress release
Johnson & Johnson reports 50% five-year treatment-free remission rate for CARVYKTI in early-line multiple myeloma
2026-09-25 11:02:41 UTC#368110updateconfirmednews
Johnson & Johnson reports 69.2% five-year survival rate for Tecvayli and Darzalex combination
2026-09-25 11:02:33 UTC#368151duplicateconfirmednews
J&J reports 50% treatment-free remission rate at five years for Carvykti in early-line multiple myeloma
2026-09-25 11:00:00 UTC#368126newconfirmedpress release
J&J's Carvykti shows 50% treatment-free remission rate at five years in early-line multiple myeloma patients
2026-09-25 09:30:00 UTC#367652newconfirmedanalysis
Protagonist Therapeutics' oral peptide platform gains traction, challenging AbbVie's market position
dow_jonesimportance 0.40trust 0.80Protagonist Therapeutics, Inc. +0.60Johnson & Johnson +0.40AbbVie Inc. -0.30+1 entities
2026-09-24 20:24:42 UTC#365327updateconfirmednews
Nanobiotix H1 2026 net loss widens to €34.3M on revenue decline; cash runway extended to 2029
2026-09-24 19:24:05 UTC#365044newconfirmednews
Johnson & Johnson reports positive Phase 3 results for Caplyta in bipolar I mania treatment
yahooimportance 0.40trust 0.60Johnson & Johnson +0.50Intra-Cellular Therapies, Inc. +0.50Caplyta +0.50
2026-09-24 10:17:00 UTC#361566newconfirmednews
Medical robots market projected to reach $41.7B by 2031 at 15.1% CAGR, ResearchAndMarkets reports
yahooimportance 0.30trust 0.60Intuitive Surgical, Inc. +0.30Stryker Corporation +0.30Zimmer Biomet Holdings, Inc. +0.30+2 entities
2026-09-23 14:35:00 UTC#356306duplicateconfirmednews
J&J reports Tecvayli and Darzalex Faspro combination improves survival in multiple myeloma patients
dow_jonesimportance 0.30trust 0.80Johnson & Johnson +0.50Tecvayli +0.50Darzalex Faspro +0.50+1 entities
2026-09-23 14:20:00 UTC#356126duplicateconfirmednews
Johnson & Johnson reports Tecvayli and Darzalex Faspro combination improves survival in multiple myeloma patients
dow_jonesimportance 0.40trust 0.80Johnson & Johnson +0.50Tecvayli +0.50Darzalex Faspro +0.50+1 entities
2026-09-23 13:46:00 UTC#355870newconfirmedpress release
J&J reports model-based analysis showing Tecvayli plus Darzalex Faspro reduces mortality risk in multiple myeloma
2026-09-22 14:11:52 UTC#349494duplicateconfirmedanalysis
Analysis: Johnson & Johnson's CAPLYTA Bipolar I Mania Data and Investment Outlook
2026-09-21 12:50:20 UTC#342567duplicateconfirmednews
J&J's Caplyta meets primary endpoint in bipolar mania study
2026-09-21 12:48:35 UTC#342556newconfirmednews
J&J reports Caplyta meets primary endpoint in late-stage bipolar mania study
reutersimportance 0.60trust 0.90Johnson & Johnson +0.50Caplyta +0.60Intra-Cellular Therapies, Inc. +0.30
2026-09-21 11:28:15 UTC#342208newconfirmednews
Contineum Therapeutics shares fall 10% after MOONLIGHT-1 trial misses primary efficacy endpoint
tradingviewimportance 0.50trust 0.70Contineum Therapeutics, Inc. -0.60Johnson & Johnson -0.30PIPE-307 -0.60+1 entities
2026-09-21 11:28:15 UTC#341991newconfirmednews
Johnson & Johnson raises 2026 guidance after Q1-Q2 beat, reports PAPILLON trial success and $5.5B talc deal
2026-09-17 20:30:00 UTC#329929duplicateconfirmedpress release
PepsiCo elects Johnson & Johnson CEO Joaquin Duato to Board of Directors effective December 1
yahooimportance 0.30trust 1.00PepsiCo, Inc. +0.10Joaquin Duato +0.10Johnson & Johnson +0.10+1 entities